Research areas

The research within MyoNet will enable us to address some questions on the role of functional biomarkers in contribution to susceptibility, severity and to prognosis of polymyositis and dermatomyositis and to different clinical, serological and histopathological subtypes.

​In order to achieve the goals within EuMyoNet, the research is organized into four areas of research that are chaired by different Steering Committe members.​

Research areas

More details on the specific research areas can be followed through the links on the left menu as well.

  • EuroMyositis registry, Prof. Ingrid Lundberg, chair​
  • Genetics project and DNA database, Prof. Robert Cooper, chair
  • ​Serology standardization and database, Prof. Pierre-André Guerne, chair
  • ​Muscle biopsy standardization and database, Prof. Jan De Bleecker, chair

Within our network we will be able to collect clinical information and biological samples including DNA, sera, plasma and muscle biopsies from the largest cohort of well-characterized patients with adult or juvenile polymyositis and dermatomyositis with longitudinal follow up in the world.​

Through the genetic studies we will gain access to information about novel genes, which could be important in the pathophysiology of myositis. This information will be further tested for its functional importance. It is through such careful analyses that genetic factors may be used to predict certain disease characteristics at the outset of disease and in the future create a diagnostic genetic and serological panel to allow diagnosis of myositis and clinical subtypes.

​It is hoped that improved information on functional biomarkers will allow development of more appropriate and targeted therapy. We will also form a database of patients that can be enrolled in future clinical trials when novel therapies are to be tested. This will attract collaborations with pharmaceutical companies and facilitate testing of new therapies within our network.

Our network model, with an electronic database register, which will be feasible to use in clinical settings, will be applied for longitudinal studies including outcome assessments of new therapies.

Comments are closed.